Bolt Biotherapeutics, Inc.

NASDAQ:BOLT

0.65 (USD) • At close September 6, 2024
Bedrijfsnaam Bolt Biotherapeutics, Inc.
Symbool BOLT
Munteenheid USD
Prijs 0.648
Beurswaarde 24,780,284
Dividendpercentage 0%
52-weken bereik 0.641 - 1.56
Industrie Biotechnology
Sector Healthcare
CEO Dr. Randall C. Schatzman Ph.D.
Website https://www.boltbio.com

An error occurred while fetching data.

Over Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with

Vergelijkbare Aandelen

Qilian International Holding Group Limited logo

Qilian International Holding Group Limited

QLI

5.41 USD

Oncolytics Biotech Inc. logo

Oncolytics Biotech Inc.

ONCY

0.958 USD

SCYNEXIS, Inc. logo

SCYNEXIS, Inc.

SCYX

1.27 USD

Bionomics Limited logo

Bionomics Limited

BNOX

0.595 USD

Seelos Therapeutics, Inc. logo

Seelos Therapeutics, Inc.

SEEL

0.228 USD

Rain Therapeutics Inc. logo

Rain Therapeutics Inc.

RAIN

1.21 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)